The financials
Supernus Pharmaceuticals, Inc. by the numbers
Supernus Pharmaceuticals, Inc. (SUPN) reported revenue of $208M in Q1 2026 (quarter ended March 31, 2026), up 39% from the same quarter a year earlier. That came with a gross margin of 89% and net loss of $2.3M. For the full year FY2025, revenue was $719M (+8.6% year on year) and net income −$39M. Its largest product in 2026-Q1 was Qelbree at $78M, 37% of the disclosed total, just ahead of GOCOVRI at 17%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $208M | $150M | +39% |
| Gross profit | $184M | $134M | +37% |
| Operating income | −$8.3M | −$10M | n/a |
| Net income | −$2.3M | −$12M | n/a |
| Diluted EPS | −$0.04 | −$0.21 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Qelbree | $78M | 37% |
| GOCOVRI | $35M | 17% |
| Royalty License And Other | $29M | 14% |
| Collaboration | $28M | 13% |
| Trokendi Xr | $9.5M | 4.6% |
| ONAPGO | $8.4M | 4.0% |
| APOKYN | $7.7M | 3.7% |
| Oxtellar XR | $7.4M | 3.6% |
| Manufactured Product Other | $4.7M | 2.2% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $207.7M (+8.1%)
Royalty License And Other grew +274% year on yearAPOKYN -48% year on year
Segment Latestquarter on quarteryear on year
- Qelbree$77.8M$77.8MQoQ -4.4%year on year +20%-4.4%+20%
- GOCOVRI$35.2M$35.2MQoQ -14%year on year +15%-14%+15%
- Royalty License And Other$29.3M$29.3MQoQ +763%year on year +274%+763%+274%
- Collaboration$27.6M$27.6MQoQ +37%year on year -+37%-
- Trokendi Xr$9.5M$9.5MQoQ -5.6%year on year -26%-5.6%-26%
- ONAPGO$8.4M$8.4MQoQ +23%year on year -+23%-
- APOKYN$7.7M$7.7MQoQ -26%year on year -48%-26%-48%
- Oxtellar XR$7.4M$7.4MQoQ -38%year on year -27%-38%-27%
- Manufactured Product Other$4.7M$4.7MQoQ -34%year on year -46%-34%-46%
Drug Manufacturers - Specialty & Generic
Ranks #19 of 28 by Smart Score